Key facts
- This page summarizes Stanislav Glezer's Form 4 filing for Inogen Inc (INGN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 May 2024, 18:14.
Stanislav Glezer - 01 May 2024 Form 4 Insider Report for Inogen Inc (INGN)
- Reporting relationship
- EVP, R&D & Chief Med. Officer
- Issuer ticker
- INGN
- Reported as of
- 01 May 2024
- Net transaction value
- -$117,700
- SEC form
- 4
- Accepted by SEC
- 03 May 2024, 18:14:57 UTC
- Prior SEC filing
- 05 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leslyn Cicekli, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stanislav Glezer filed Form 4 for Inogen Inc (INGN) on 03 May 2024.
Change
- Previous filing in this sequence was filed on 05 Mar 2024.
- Current net transaction value: -$117,700.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INGN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +32,638
- Change %
- +203%
- Price
- $0.000000
- Shares after
- 48,744
- Date
- 01 May 2024
- Ownership
- Direct
INGN
transaction
Common Stock
Tax liability
- Transaction value
- $117,700
- Shares
- -16,695
- Change %
- -34%
- Price
- $7.05
- Shares after
- 32,049
- Date
- 01 May 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INGN
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -32,638
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,638
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on May 1, 2024.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.
Footnote F3
Subject to the reporting person's continued service, one hundred percent (100%) of the restricted stock units shall vest on May 1, 2024